Q3 2024 Geron Corp Earnings Call Transcript
Key Points
- Geron Corp (GERN) achieved $28.2 million in Rytelo net product revenue in its first full quarter, exceeding expectations.
- The company has a strong intellectual property position, with exclusivity in the U.S. through August 2037 for Rytelo.
- Geron Corp (GERN) completed a synthetic royalty transaction and a debt financing transaction, generating $250 million in gross proceeds.
- The company has achieved significant payer coverage for Rytelo, with policies covering approximately 70% of U.S. covered lives.
- Geron Corp (GERN) is preparing for potential EU commercialization of Rytelo, with expected approval in the first half of 2025.
- The company faces potential fluctuations in weekly sales data, which may not fully capture internal insights.
- Geron Corp (GERN) is still in the early stages of Rytelo's launch, with potential variability in growth trajectory.
- The company has significant operating expenses, with total operating expenses for the nine months ended September 30, 2024, at $183.1 million.
- There is a dependency on achieving internal revenue projections to reach break-even without additional financing.
- The company is facing competition in the first-line treatment setting from other therapies like luspatercept.
Hello and welcome to the Geron third quarter, 2024 earnings call. (Operator Instructions) I would now like to turn the conference over to Aron Feingold, Vice President of Investor Relations and corporate communications. You may begin.
Good morning, everyone. Welcome to the Geron Corporation third quarter, 2024 earnings conference call. I am Aron Feingold, Geron's Vice President of Investor relations and corporate communications. I'm joined today by several members of Geron's management team.
Dr. John Scarlett, Chairman and Chief Executive Officer; Michelle Robertson, executive Vice President and Chief Financial Officer; Jim Ziegler, executive Vice President and Chief Commercial Officer; Dr. Faye Feller, executive Vice President and Chief Medical Officer and Dr. Andrew Grethlein, executive Vice President and Chief Operating Officer.
Before we begin. Please note that during the course of this presentation and question and answer session, we will be making
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
